European Cancer Organisation
login
close
Forgot password

* Mandatory fields

Create account

Call for Abstracts

ABSTRACT SUBMISSION IS NOW CLOSED

 

  • Abstract submission opens:  Monday, 2 December 2013
  • Deadline Abstract submission: Wednesday, 5 March 2014 (23:00 Central European Time)
  • Please note that abstracts can only be submitted online 
  • Please carefully read the abstract regulations before submitting your abstract

 

Abstract Regulations

With the submission of an abstract to EACR-23, the first author (presenting author):

  • Accepts responsibility for the accuracy of the submitted abstract.
  • Confirms that all authors are aware of and agree to the content of the abstract and support the data presented.
  • Warrants that the data and conclusions presented in the abstract have not been published in the same format and with the same title prior to the date of the conference.
  • Identifies any financial interest in products or processes described in the abstract. This information is to be forwarded to the Scientific Committee together with the abstract.
  • States that, for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate.
  • Gives permission for the abstract, when selected for presentation (oral or poster), to be published in the Congress Proceedings. Submitted abstracts cannot be withdrawn after 5 April 2014.

 

Abstract Format

In order to be considered, an abstract should respect the following guidelines: 

  • The abstract must be submitted in good English.  The Scientific Committee reserves the right to reject those abstracts, which are presented in poor English, or may request an immediate revision by the presenter.
  • Abstract titles should be brief and should reflect the content of the abstract.
  • Commercial names may not be used in the abstract title.
  • No more than 10 authors can be listed.  Only institutional affiliations, cities and countries should follow. 
  • Abstracts on “trials in progress can be submitted for EACR23 and will be considered for oral or poster presentation as long as they contain at least some preliminary and presentable results. The decision regarding inclusion in the programme and type of presentation will be decided by the Scientific Programme Committee.
  • Abbreviations may be used if standard or if spelled out and defined at the first use.  Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.
  • Supplementary data or appendices will not be accepted.
  • Figures or photographs are not allowed. Symbols and structures of drugs are allowed and should be drawn in black.
  • Abstracts should be organised under the headings:

    • Introduction
    • Material and method
    • Results and discussion
    • Conclusion
  • The online abstract submission procedure will not accept abstracts that exceed 2,500 characters (body of the abstract).
  • Abbreviations may be used if standard or if spelled out and defined at the first use.  Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.
  • Supplementary data or appendices will not be accepted.
  • Figures or photographs are not allowed. Symbols and structures of drugs are allowed and should be drawn in black.

Only the submitting author will receive a confirmation/abstract number by e-mail from the EACR-23 Congress Secretariat within 24 hours of submission. This confirmation of abstract receipt is NOT a notice of acceptance.

For questions regarding the online submission process, please contact Rebekka Mattyasovszky:    
E-mail: rebekka.mattyasovszky@ecco-org.eu

 

Further information:

 



 

PRINT THIS PAGE Page last modified: